Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Molecular Biomarkers for Cancer Targeted Therapeutics"
A special issue of Diagnostics (ISSN 2075-4418).
Deadline for manuscript submissions: closed (15 November 2012).
Interests: biomarkers in clinical application; molecular diagnostics; signaling pathway in cancer biology
Advances in cancer genetics and molecular techniques are providing increased opportunities for molecular diagnostics in cancer. Cancer molecular tests typically analyze nucleic acid-based biomarkers and can be classified based on clinical application as diagnostic, prognostic, and predictive. Cancer diagnostic tests are used for cancer screening, diagnosis, subtyping, and staging; cancer prognostic tests reveal the nature course of cancer, disease outcome and recurrence following treatment; whereas cancer predictive tests provide information on the likely response of a patient to a drug or therapy. Often, a single molecular oncology test can find its application in more than one categories based on the clinical scenario. Molecular tests are expected to have ever-increasing impact on clinical management of cancer patients. For example, molecular diagnostics are developed to select patients who will benefit to a targeted therapeutics, to monitor the development of treatment resistance, to assess recurrence following treatment, to modify the dose of a therapeutic, and to identify the pharmacogenetic risk of adverse drug reactions. This way, correct treatment is determined per patient, non-effective treatments can be spared, and side-effects avoided, thus leading to personalized and precision cancer management.
Dr. Jianli Dong
- cancer molecular diagnostics
- nucleic acid
- companion molecular diagnostics
- molecular targeted therapy